Shots:
- Concentra Biosciences has entered into a definitive merger agreement to acquire iTeos Therapeutics
- As per the deal, iTeos Therapeutics’ shareholders will receive $10.047 per share in cash, along with a non-transferable CVR, which entitles them to 100% of iTeos’ net cash exceeding $475M at closing & 80% of net proceeds from the sale of specified product candidates occurring within 6mos. post-closing
- The transaction is anticipated to be completed in the Q3’25, subject to the satisfaction or waiver of customary closing conditions
Ref: Globenewswire | Image: iTeos Therapeutics | Press Release
Related News:- Sanofi to Acquire Vicebio for ~$1.6B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
